These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1069 related articles for article (PubMed ID: 18435669)

  • 1. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study.
    Alvarez Guisasola F; Mavros P; Nocea G; Alemao E; Alexander CM; Yin D
    Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():8-15. PubMed ID: 18435669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study.
    Alvarez Guisasola F; Tofé Povedano S; Krishnarajah G; Lyu R; Mavros P; Yin D
    Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():25-32. PubMed ID: 18435671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary.
    Jermendy G; ; Erdesz D; Nagy L; Yin D; Phatak H; Karve S; Engel S; Balkrishnan R
    Health Qual Life Outcomes; 2008 Oct; 6():88. PubMed ID: 18976457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression to insulin for patients with diabetes mellitus on dual oral antidiabetic therapy using the US Department of Defense Database.
    Rascati K; Richards K; Lopez D; Cheng LI; Wilson J
    Diabetes Obes Metab; 2013 Oct; 15(10):901-5. PubMed ID: 23531154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study.
    Montvida O; Shaw JE; Blonde L; Paul SK
    Diabetes Obes Metab; 2018 Jul; 20(7):1722-1731. PubMed ID: 29536608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.
    Schwarz B; Gouveia M; Chen J; Nocea G; Jameson K; Cook J; Krishnarajah G; Alemao E; Yin D; Sintonen H
    Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():43-55. PubMed ID: 18435673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
    Lukashevich V; Del Prato S; Araga M; Kothny W
    Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors Associated with Type 2 Diabetes Mellitus Treatment Choice Across Four European Countries.
    Heintjes EM; Overbeek JA; Hall GC; Prieto-Alhambra D; Lapi F; Hammar N; Bezemer ID
    Clin Ther; 2017 Nov; 39(11):2296-2310.e14. PubMed ID: 29108837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.
    Hollander P; Sugimoto D; Vlajnic A; Kilo C
    J Diabetes Complications; 2015; 29(8):1266-71. PubMed ID: 26281972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany.
    Khunti K; Godec TR; Medina J; Garcia-Alvarez L; Hiller J; Gomes MB; Cid-Ruzafa J; Charbonnel B; Fenici P; Hammar N; Hashigami K; Kosiborod M; Nicolucci A; Shestakova MV; Ji L; Pocock S
    Diabetes Obes Metab; 2018 Feb; 20(2):389-399. PubMed ID: 28817227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world Evaluation of glycemic control and hypoglycemic Events among type 2 Diabetes mellitus study (REEDS): a multicentre, cross-sectional study in Thailand.
    Satirapoj B; Pratipanawatr T; Ongphiphadhanakul B; Suwanwalaikorn S; Benjasuratwong Y; Nitiyanant W
    BMJ Open; 2020 Feb; 10(2):e031612. PubMed ID: 32051301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin in type 2 diabetes: a useful alternative despite limited assessment based on surrogate endpoints.
    Prescrire Int; 2005 Oct; 14(79):187-93. PubMed ID: 16285076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18).
    Scheen AJ; Tan MH; Betteridge DJ; Birkeland K; Schmitz O; Charbonnel B;
    Diabet Med; 2009 Dec; 26(12):1242-9. PubMed ID: 20002476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents.
    Olansky L; Reasner C; Seck TL; Williams-Herman DE; Chen M; Terranella L; Mehta A; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2011 Sep; 13(9):841-9. PubMed ID: 21535346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of hypoglycemia among a sample of sulfonylurea-treated patients with Type 2 diabetes mellitus in Argentina: The real-life effectiveness and care patterns of diabetes management (RECAP-DM) study.
    Gonzalez C; Monti C; Pinzon A; Monsanto H; Ejzykowicz F;
    Endocrinol Diabetes Nutr (Engl Ed); 2018 Dec; 65(10):592-602. PubMed ID: 30076124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression to insulin for patients with diabetes mellitus using the Texas Medicaid database.
    Rascati KL; Richards KM; Lopez D; Cheng LI; Wilson JP
    Clin Ther; 2011 Dec; 33(12):2016-20. PubMed ID: 22101160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Outcomes After Initiating Triple Antidiabetic Therapy with a GLP-1 RA in an Integrated Health Care System.
    Lee SM; Aboubechara N; Niu F; Ledesma VM; Patel YA; Millares M; Hui RL
    J Manag Care Spec Pharm; 2019 Mar; 25(3):350-356. PubMed ID: 30816819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Dipeptidyl Peptidase-4 Inhibitors versus Thiazolidinediones or Insulin in Patients with Type 2 Diabetes Uncontrolled with Metformin and a Sulfonylurea in a Real-World Setting.
    Aboubechara N; Ledesma VM; Niu F; Lee SM; Patel YA; Millares M; Hui RL
    Perm J; 2020 Nov; 24():1-8. PubMed ID: 33482956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.